Cumberland Pharma Announces Availability Of Vibativ 4-Vial Starter Pak Through New Contract With Vizient

Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers

NASHVILLE, Tenn., Aug. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced the availability of the Vibativ® (telavancin) 4-Vial Starter Pak through a new contract with Vizient®, the nation's largest provider-driven healthcare performance improvement company.

Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers and 35% of the non-acute market. Through this agreement, Vizient members now have increased access to Vibativ's new 4-vial configuration, which supports flexible treatment initiation in both inpatient and outpatient settings for this potentially life-saving therapy.

Vibativ is an FDA-approved injectable antibiotic indicated for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), as well as complicated skin and skin structure infections (cSSSI) caused by Gram-positive pathogens, including MRSA.